Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 4/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albizziine SCHEMBL9361011 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL439790 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL1006298 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL1006299 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL29791573 | 0.98 | GFPT1 (0.47) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL31524073 | 0.82 | CYP2D6 (0.50) | GFPT1PTGS1SLC7A11GGT1SLC7A5 | |
| SCHEMBL1527344 | 0.81 | GFPT1 (0.46) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL574087 | 0.81 | GFPT1 (0.46) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL393844 | 0.81 | GFPT1 (0.46) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL1512859 | 0.81 | SLC7A5 (0.43) | ALOX15BLMPMP22KMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | claimed |
| EP-4359377-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-05-01 | — | — | EP | claimed |
| CN-117750978-A | Synthetic peptide shuttle bioconjugates for intracellular cargo delivery | 费尔丹生物公司 | 2024-03-22 | — | — | CN | claimed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | claimed |
| EP-4232590-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Feldan Bio Inc. (CA) | 2023-08-30 | — | — | EP | claimed |
| EP-4229207-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | Feldan Bio Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| CN-116615205-A | Peptide-based transduction of non-anionic polynucleotide analogs for modulation of gene expression | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| CN-116615227-A | Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| US-20230019098-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | RISEN (SHANGHAI) MEDICINAL TECH CO., LTD. (CN) | 2023-01-19 | — | — | US | claimed |
| EP-0910655-A4 | VACCINES FOR TREATMENT OF LYMPHOMA AND LEUKEMIA | GENITOPE CORP (US) | 2006-05-03 | — | — | EP | claimed |
| US-20040096452-A1 | Vaccines for treatment of lymphoma and leukemia | DENNEY DAN W (US) | 2004-05-20 | — | — | US | claimed |
| US-20020160006-A1 | Methods of treating lymphoma and leukemia | DENNEY DAN W (US) | 2002-10-31 | — | — | US | claimed |
| US-6191168-B1 | BACTERICIDES | Rubenstein, Edward | 2001-02-20 | — | — | US | claimed |
| US-5972334-A | IMPROVED METHODS FOR THE AMPLIFICATION AND EXPRESSION OF RECOMBINANT GENES IN CELLS. THE AMPLIFIED CELLS PROVIDE LARGE QUANTITIES OF RECOMBINANT PROTEINS SUITABLE FOR IMMUNOTHERAPY FOR TREATMENT OF LYMPHOMAS AND LEUKEMIAS. | GENITOPE CORPORATION | 1999-10-26 | — | — | US | claimed |
| EP-0910655-A1 | VACCINES FOR TREATMENT OF LYMPHOMA AND LEUKEMIA | Genitope Corporation (US) | 1999-04-28 | — | — | EP | claimed |
| US-5776746-A | EFFICIENT ISOLATION OF AMPLIFIED CELL LINES WHICH EXPRESS THEPROTEINS OF INTEREST IN A RELATIVELY SHORT PERIOD OF TIME | GENITOPE CORPORATION (US) | 1998-07-07 | — | — | US | claimed |
| WO-1997041244-A1 | VACCINES FOR TREATMENT OF LYMPHOMA AND LEUKEMIA | GENITOPE CORPORATION (US) | 1997-11-06 | — | — | WO | claimed |
| US-5011776-A | Shuttle vector, utilizing the E. coli asparagine synthetase gene, and capable of dominant transfection and amplification in animal cells | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING (MCGILL UNIVERSITY) (CA) | 1991-04-30 | — | — | US | claimed |
| EP-0319206-A2 | Gene amplification | BERLEX LABORATORIES, INC. (US) | 1989-06-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | SCAMP2, SLC7A1, NUMA1 | GFPT1 1712/4885ALOX15 4632/4885BLM 2300/4885 |
| US-20230019098-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | PLK1, BRDT, BCR | GFPT1 4407/4885ALOX15 3690/4885BLM 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.